Correspondence 0001104659-23-128771 from Gain Therapeutics, Inc. (GANX) (CIK 0001819411) (GANX)
Gain Therapeutics, Inc. (GANX) (CIK 0001819411)
Date: Dec. 22, 2023 · CIK: 0001819411 · Accession: 0001104659-23-128771
AI Filing Summary & Sentiment
File numbers found in text: 333-276145
Letter
Re: Gain Therapeutics, Inc. (the “Company”)
December 22, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (File No. 333-276145)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:01 p.m., Eastern Time, on December 29, 2023, or as soon as practicable thereafter.
Please call Steven M. Skolnick, Esq. of Lowenstein Sandler LLP at 973-597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
GAIN THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
December 22, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Gain Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-276145)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 4:01 p.m., Eastern Time, on December 29, 2023, or
as soon as practicable thereafter.
Please call Steven M. Skolnick,
Esq. of Lowenstein Sandler LLP at 973-597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
GAIN THERAPEUTICS, INC.
By:
/s/ C. Evan Ballantyne
Name:
C. Evan Ballantyne
Title:
Chief Financial Officer